Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research Expects JD HEALTH to Sustain Vigorous Growth; Rating Upgraded to Buy with TP HKD65
Recommend 7 Positive 13 Negative 1 |
||||
|
||||
|
JD HEALTH (06618.HK)'s 2Q25 results beat expectations, with growth in advertising and pharmaceuticals benefiting from the company's strong supply chain capabilities, according to a HSBC Global Research report. Despite its continued offline and AI investments, the broker predicted JD HEALTH to sustain its growth momentum and maintain steady profit margins. HSBC Global Research raised its target price for JD HEALTH from HKD49 to HKD65, indicating an upside potential of about 19%. Its rating was also upgraded from Hold to Buy. The broker cited that JD HEALTH not only achieved revenue growth beyond expectations, but also benefited from favorable revenue mix shifts and better-than-expected fulfillment cost control, contributing to a strong earnings outlook. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
